Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.
Separating the winners from the value traps is a tough challenge, and that’s where StockStory comes in. Our job is to find you high-quality companies that will stand the test of time. That said, here are three value stocks with little support and some other investments you should consider instead.
Collegium Pharmaceutical (COLL)
Forward P/E Ratio: 3.2x
Pioneering abuse-deterrent technology in a field plagued by addiction concerns, Collegium Pharmaceutical (NASDAQ: COLL) develops and markets specialty medications for treating moderate to severe pain, including abuse-deterrent opioid formulations.
Why Are We Cautious About COLL?
- Smaller revenue base of $808.2 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- Estimated sales growth of 3.9% for the next 12 months implies demand will slow from its two-year trend
- Day-to-day expenses have swelled relative to revenue over the last two years as its adjusted operating margin fell by 7.6 percentage points
Collegium Pharmaceutical’s stock price of $22.53 implies a valuation ratio of 3.2x forward P/E. Check out our free in-depth research report to learn more about why COLL doesn’t pass our bar.
Essent Group (ESNT)
Forward P/B Ratio: 1x
Serving as a crucial bridge between homebuyers and the American dream of homeownership, Essent Group (NYSE: ESNT) provides private mortgage insurance and title services that enable lenders to offer home loans with down payments of less than 20%.
Why Are We Wary of ESNT?
- 1.8% annualized net premiums earned growth over the last two years lagged behind its insurance peers
- Expenses have increased as a percentage of revenue over the last two years as its pre-tax profit margin fell by 9.8 percentage points
- Incremental sales over the last two years were less profitable as its 1.9% annual earnings per share growth lagged its revenue gains
At $63.75 per share, Essent Group trades at 1x forward P/B. If you’re considering ESNT for your portfolio, see our FREE research report to learn more.
Atmus Filtration Technologies (ATMU)
Forward P/E Ratio: 14.3x
Spun out of Cummins in 2023 after 65 years as part of the engine maker, Atmus Filtration Technologies (NYSE: ATMU) manufactures filters for trucks, construction equipment, and agriculture machinery to reduce emissions and protect engines.
Why Are We Hesitant About ATMU?
- 6.1% annual revenue growth over the last five years was slower than its industrials peers
- Gross margin of 26.7% reflects its high production costs
Atmus Filtration Technologies is trading at $44.73 per share, or 14.3x forward P/E. To fully understand why you should be careful with ATMU, check out our full research report (it’s free).
Stocks We Like More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
